Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents

Since BNT162b2 was approved to prevent COVID-19 in children, we aim to compare the safety and immunogenicity of the BNT162b2 vaccine in liver-transplanted (LT) and healthy adolescents. LT and healthy adolescents received two doses of 30 µg of BNT162b2. All were evaluated for total COVID-19 antibodie...

Descripción completa

Detalles Bibliográficos
Autores principales: Sintusek, Palittiya, Buranapraditkun, Supranee, Khunsri, Siriporn, Saengchaisukhonkit, Varattaya, Vichaiwattana, Preeyaporn, Srimuan, Donchida, Thongmee, Thanunrat, Poovorawan, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413008/
https://www.ncbi.nlm.nih.gov/pubmed/36016212
http://dx.doi.org/10.3390/vaccines10081324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413008/
https://www.ncbi.nlm.nih.gov/pubmed/36016212
http://dx.doi.org/10.3390/vaccines10081324

Ejemplares similares